Anti-tumor effects of 10-hydroxycamptothecinc-treated DC-Hepa1-6 fusion vaccines.
- Author:
Wen-gang SONG
1
;
Xun QU
;
Ya-lin LI
;
Ying-ping XU
;
Cong WU
;
Qing-liang QIN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antineoplastic Agents, Phytogenic; pharmacology; Apoptosis; Camptothecin; analogs & derivatives; pharmacology; Cancer Vaccines; administration & dosage; genetics; immunology; Cell Fusion; Cytotoxicity, Immunologic; Dendritic Cells; immunology; transplantation; Female; Liver Neoplasms; immunology; pathology; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Rats; T-Lymphocytes, Cytotoxic; immunology; Tumor Cells, Cultured
- From: Chinese Journal of Hepatology 2004;12(6):344-346
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the induction of antitumor immune responses and therapeutic effects of 10-hydroxycamptothecinc-treated (HCPT) DC-Hepa fusion vaccines by DC fused with hepal-6 cell from hepatoma.
METHODSThe fused cells were isolated by magnetic cell sorting and adherent culture. Cell apoptosis was detected by Rhodamine123/PI double-labeled assay, CTL activity by 4 h (51)Cr releasing assay. Protective and therapeutic effects of the fusion vaccine to the tumor-bearing mice was also observed.
RESULTSThe apoptosis rate was 29.7%+/-4.1% when DC-Hepa fusion vaccine was treated with 50 microg/ml HCPT for 24 h. After treatment with the HCPT-DC-Hepa fusion vaccine, the tumor grew obviously slowly, survival period of the mice was prolonged, induced more potent CTL cytotoxicity, and resisted against the rechallenge of Hepal-6 cells.
CONCLUSIONVaccination with HCPT-DC-Hepa fusion vaccine could elicit potent antitumor responses, which will provide a new approach to the DC-mediated therapeutic antitumor immunity.
